/

Other

/

Taiho Oncology, Inc.

Taiho Oncology, Inc.

Taiho Oncology, Inc.

Verified Nov 2026

Other

·

United States flag

Princeton, New Jersey

·

Since 2002

Taiho Oncology, Inc. is a clinical development and commercialization organization focused on oncology drugs, headquartered in Princeton, New Jersey, and founded in 2002. The company operates as the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., part of Otsuka Holdings Co., Ltd., with 200–500 employees and estimated revenue of $250–500M. It specializes in small-molecule anti-cancer agents targeting solid tumors and hematological malignancies, and recently completed FDA filing for zipalertinib in combination therapy for first-line lung cancer.

Taiho Oncology, Inc.

Verified Nov 2026

AT A GLANCE

Founded

2002

Headquarters

United States flag

Princeton, New Jersey

Employees

200-500

Ownership

Taiho Oncology, Inc. at a glance

Revenue

$250-500M

Est. band

Employees

200-500

Founded

2002

Headquarters

Princeton, New Jersey

Industries

Automotive

Electric Vehicles

Medical

Overview

Taiho Oncology, Inc. is a clinical development and commercialization organization focused on oncology drugs, headquartered in Princeton, New Jersey, and founded in 2002. The company operates as the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., part of Otsuka Holdings Co., Ltd., with 200–500 employees and estimated revenue of $250–500M. It specializes in small-molecule anti-cancer agents targeting solid tumors and hematological malignancies, and recently completed FDA filing for zipalertinib in combination therapy for first-line lung cancer.

At a glance

Attribute

Detail

Founded

2002

Headquarters

Princeton, New Jersey

Employees

200-500

Revenue

$250-500M (estimated)

What Taiho Oncology, Inc. makes

Taiho Oncology oversees clinical development of small-molecule anti-cancer agents from pre-clinical research through multiple trial phases, and manages commercialization and post-market activities for approved drugs in the U.S., Canada, and Europe.

Latest developments

Facilities

Taiho Oncology, Inc. is headquartered in Princeton, New Jersey. Public sources also reference these locations:

Company details

The company operates as a U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., which is owned by Otsuka Holdings Co., Ltd., and maintains facilities in Princeton, New Jersey, and Baar, Switzerland. Taiho Oncology, Inc. was founded in 2002, has an estimated 200-500 employees, and is headquartered in Princeton, New Jersey.

Frequently asked questions

What does Taiho Oncology, Inc. do?

Taiho Oncology, Inc. is a clinical development and commercialization organization focused on oncology drugs, headquartered in Princeton, New Jersey, and founded in 2002. The company operates as the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., part of Otsuka Holdings Co., Ltd., with 200–500 employees and estimated revenue of $250–500M. It specializes in small-molecule anti-cancer agents targeting solid tumors and hematological malignancies, and recently completed FDA filing for zipalertinib in combination therapy for first-line lung cancer.

Where is Taiho Oncology, Inc. headquartered?

Taiho Oncology, Inc. is headquartered in Princeton, New Jersey (101 Carnegie Center Drive, Princeton, New Jersey, 08540).

When was Taiho Oncology, Inc. founded?

Taiho Oncology, Inc. was founded in 2002.

How big is Taiho Oncology, Inc.?

Taiho Oncology, Inc. has an estimated 200-500 employees, with revenue in the $250-500M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Princeton, New Jersey (HQ)Headquarters · United States
Princeton, New Jersey (HQ)101 Carnegie Center Drive, Princeton, New Jersey, 08540, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.